189132-01-2

Basic information

• Product Name: (4-IODO-BENZYL)-CARBAMIC ACID TERT-BUTYL ESTER
• Synonyms: (4-IODO-BENZYL)-CARBAMIC ACID TERT-BUTYL ESTER;tert-Butyl 4-Iodobenzylcarbamate
• CAS NO: 189132-01-2
• Molecular Formula: C₁₂H₁₆INO₂
• Molecular Weight: 333.17
• Mol File: 189132-01-2.mol
• Article Data: 20

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (4-IODO-BENZYL)-CARBAMIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (4-IODO-BENZYL)-CARBAMIC ACID TERT-BUTYL ESTER(189132-01-2)
• EPA Substance Registry System: (4-IODO-BENZYL)-CARBAMIC ACID TERT-BUTYL ESTER(189132-01-2)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 189132-01-2(Hazardous Substances Data)

Usage

General Description

(4-Iodo-benzyl)-carbamic acid tert-butyl ester is a chemical compound with the molecular formula C13H18INO2. It is an ester derivative of carbamic acid, and its main use is as an intermediate in the synthesis of pharmaceuticals and agrochemicals. The compound is a white to off-white solid with a molecular weight of 323.19 g/mol. It is considered to be stable under normal conditions and is not expected to pose any significant health or environmental hazards when handled and used properly. The compound's main applications include its use as a building block in organic synthesis and in the development of new chemical compounds for various industries.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 39959-59-6 4-iodobenzyl amine 
• 680190-94-7 1-azidomethyl-4-iodo-benzene 
• 619-58-9 4-iodobenzoic acid 
• 18282-51-4 4-iodo-benzyl alcohol 
• 16004-15-2 1-bromomethyl-4-iodobenzene 
• 84250-74-8 (4-iodophenyl)methanamine hydrochloride 
• 34619-03-9 tert-butyldicarbonate 
• 59528-27-7 p-iodobenzylamine hydrochloride 
• 26177-44-6 4-bromobenzylamine hydrochloride 
• 68819-84-1 tert-butyl N-(4-bromobenzyl)carbamate 

Downstream Products

• 874568-69-1 bis-(4-iodo-benzyl)-carbamic acid tert-butyl ester 
• 1381949-73-0 ditert-butyl ((ethyne-1,2-diylbis(4,1-phenylene))bis(methylene))dicarbamate 
• 773128-23-7 tert-butyl (4-iodobenzyl)(methyl)carbamate 
• 1482499-10-4 C₂₉H₂₆Fe₂N₂O₇S₂ 
• 1269071-39-7 C₁₉H₂₁NO₃S 
• 1228098-23-4 C₁₇H₂₆N₂O₃ 
• 1049807-85-3 (4-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-carbamic acid tert-butyl ester 
• 1067465-98-8 C₃₀H₂₉NO₂ 
• 496945-41-6 tert-butyl 4-(2-formylethyl)benzylcarbamate 
• 1027586-35-1 [(S)-5-[(S)-3-tert-Butoxy-2-(2-{4-[4-(tert-butoxycarbonylamino-methyl)-phenylethynyl]-phenyl}-acetylamino)-propionylamino]-5-(2-cyclohexyl-ethylcarbamoyl)-pentyl]-carbamic acid tert-butyl ester 

Relevant articles and documents

Luminescence and Relaxometric Properties of Heteropolymetallic Metallostar Complexes with Selectively Incorporated Lanthanide(III) Ions

The synthesis and characterization of two diethylenetriaminepentaacetic acid (DTPA) based heteropolymetallic metallostar lanthanide complexes with the general formulas (GdL1)3Ln and (GdL2)3Ln are described. The

First Contact: 7-Phenyl-2-Aminoquinolines, Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors That Target an Isoform-Specific Aspartate

Inhibition of neuronal nitric oxide synthase (nNOS), an enzyme implicated in neurodegenerative disorders, is an attractive strategy for treating or preventing these diseases. We previously developed several classes of 2-aminoquinoline-based nNOS inhibitor

ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The present invention relates to a compound suitable for use as a kinase inhibitor according to general formula (I) [compound (C), herein after], or the N- oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof, formula (I) wherein A, R1, R2, R3, R3', R4, R4', X, Y, Z, T are as defined in the claims. The invention further relates to an in vitro method of inhibiting protein kinase activity which comprises contacting a protein kinase with a compound of formula (I), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof. The invention further relates to the compounds of formula (I) per se, as well as to their use as a medicament, and for use or in a method of treatment of a disease mediated by a protein kinase selected from cancer, inflammatory disorders, cardiovascular diseases, viral induced diseases, circulatory diseases, fibro-proliferative diseases and pain sensitization disorders.